Drugs / Trichuris suis ova
Trichuris suis ova
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01948271 | Jul 2013 → Sep 2014 | psoriasis | Tufts Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT01040221 | Nov 2012 → Jun 2014 | autism | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01434693 | Nov 2011 → Apr 2012 | Crohn disease | Coronado Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01070498 | Feb 2010 → Dec 2011 | food allergy | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01413243 | Sep 2012 → Dec 2016 | multiple sclerosis | Charite University, Berlin, Germany | Terminated | No outcome recorded |
| Phase 2 | NCT01576471 | Jul 2012 → Oct 2013 | Crohn disease | Coronado Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01279577 | Nov 2010 → Feb 2014 | Crohn disease | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01006941 | May 2010 → Jan 2011 | multiple sclerosis | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01433471 | Aug 2012 → May 2015 | ulcerative colitis | NYU Langone Health | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT01836939 Comparator | Mar 2013 → Sep 2014 | psoriasis | Mark Lebwohl | Completed | No outcome recorded |
| Phase 2 | NCT03565939 Comparator | May 2018 → Jan 2022 | ulcerative colitis | ParaTech A/S | Completed | No outcome recorded |
| Phase 2 | NCT02140112 Comparator | May 2014 → Apr 2015 | autism | Coronado Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02011269 Comparator | Mar 2014 → Jan 2015 | psoriasis | Coronado Biosciences, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trichuris suis ova | “Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease” NCT01279577 ↗12“CNDO 201 Trichuris suis ova (TSO)” NCT01836939 ↗ |
| Known as | CNDO 201 | “A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12...” NCT01576471 ↗1“of Oral CNDO 201 Trichuris Suis Ova Suspension (Tso) in Patients With Crohn's Disease” NCT01434693 ↗ |
| Known as | TSO | “Inflammatory mechanisms are implicated in the aetiology of autism spectrum disorder (ASD), and use of the immunomodulator Trichuris suis Ova (TSO) is a novel treatment approach.” PMID 30230399 ↗ Nov 20185“of Oral CNDO 201 Trichuris Suis Ova Suspension (Tso) in Patients With Crohn's Disease” NCT01434693 ↗ “Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease” NCT01279577 ↗ “Probiotic Treatment of Ulcerative Colitis With Trichuris Suis Ova (TSO)” NCT03565939 ↗ “Trichuris suis ova (TSO)” NCT01576471 ↗ “Trichuris suis ova (TSO)” NCT01070498 ↗ |
| Modality | Other / unclassified | “use of the immunomodulator Trichuris suis Ova (TSO)” PMID 30230399 ↗ Nov 2018 |
| Route | Oral | “patients received 2500 ova from the helminth Trichuris suis orally every second week for 12 weeks.” PMID 25698173 ↗ Feb 2015 |